Sanofi prepares early distribution of Beyfortus to counter RSV

Sanofi announced that it will begin global deliveries of Beyfortus (nirsevimab) in the early third quarter. This initiative aims to prepare healthcare professionals ahead of the 2025-2026 respiratory syncytial virus (RSV) season, which typically begins in November. Since its launch in 2023, demand for Beyfortus has increased significantly, leading Sanofi and its partner AstraZeneca to triple their production capacity.

Beyfortus is recognized for its high efficacy against RSV and is available for all infants, regardless of their health condition or premature birth. Protection now extended to six months allows for continued coverage during the RSV season. This extension is particularly significant for newborns and children up to 24 months.